title: Intravenous immunoglobulin therapy influences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortions.
abstract: OBJECTIVE
  To determine activated T cell adhesion level to extracellular matrix (ECM) in non-pregnant women with a history of recurrent spontaneous abortions (RSA). In addition, to evaluate a small-dose intravenous immunoglobulin (IVIG) therapy influences on T cell adhesion to ECM.
  
  
  METHODS
  Phytohemaglutinin (PHA) or phorbol myristate acetate (PMA) activated T cell adhesion to the following extracellular matrix proteins: collagen IV, fibronectin and elastin were studied in women with the history of RSA. In addition, IVIG immunotherapy influence on T cell adhesion was studied. Normal T cells adhesion values were established in non-pregnant healthy women with the previous successful pregnancy outcome and in normal healthy pregnant women.
  
  
  RESULTS
  PHA activated T cell adhesion to collagen IV (P = 0.04), fibronectin (P = 0.0003) nad elastin (P = 0.02) were significantly higher in women with the history of RSA when compared to non-pregnant healthy women wit the previous successful pregancy outcome. IVIG immunotherapy normalized the T cell adhesion level and favored a successful pregnancy.
  
  
  CONCLUSIONS
  Increased T cell adhesion to collagen IV, fibronectin and elastin characterize women with the history of RSA. Decreased T cell adhesion to the main extracellular matrix components of human placenta may underlie possible effect of IVIG action.
authors.affiliation: Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław. jerzak@immuno.iitd.pan.wroc.pl
authors.forename: M
authors.initials: M
authors.lastname: Jerzak
authors.forename: T
authors.initials: T
authors.lastname: Rechberger
authors.forename: A
authors.initials: A
authors.lastname: Górski
mesh_terms: D000026:Abortion, Habitual / Q000276:immunology / Q000628:therapy*; D000328:Adult; D002448:Cell Adhesion; D005109:Extracellular Matrix / Q000502:physiology*; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D011247:Pregnancy; D013601:T-Lymphocytes / Q000187:drug effects*
chemical_list: D016756:Immunoglobulins, Intravenous